PBI targets multi-billion $ markets of human and animal vaccines, and bio-therapeutics ( ~$175 billion markets). Using our RNAi and gene-editing techniques (http://www.ncbi.nlm.nih.gov/pubmed/26581994), we customize partner cell lines to significantly reduce manufacturing costs & COGS, while significantly increasing product yield…altogether, significantly decreasing costs supplying both 1st world & previously neglected underdeveloped countries.